Exact Sciences (EXAS) Misses Q1 EPS by 21c, Updates Guidance

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.54), $0.21 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $707 million versus the consensus estimate of $688.78 million.

GUIDANCE:

Exact Sciences sees FY2025 revenue of $3.07-3.12 billion, versus the consensus of $3.9 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Crude Inventory Rose 2.97 Million Barrels Last Week - EIA
• KB Home (KBH) Tops Q3 EPS by 16c
• The New York Times Co. (NYT) call put ratio 2.3 calls to 1 put with a focus on February 220 calls as share price down 1.9%